Hormone Monitoring Partnerships

Bayer has announced a partnership with Impli, a Swiss Femtech start-up specializing in precision care. The collaboration aims to advance the development of real-time hormone monitoring devices, with a focus on improving women's health and making fertility treatments more accessible, safer, and successful. Impli's innovative technology, which involves implantable biosensors, has the potential to provide continuous monitoring of hormone levels, offering valuable insights for fertility specialists and other healthcare applications. The partnership will also explore various use cases for hormone monitoring and provide Impli with access to Bayer's global innovation ecosystem.

The collaboration is part of Bayer's broader strategy to embrace digital health technologies and enhance its precision health initiatives. By partnering with cutting-edge innovators like Impli, Bayer aims to address significant consumer needs, such as better understanding hormonal health and its impact on conditions like stress, sleep, weight management, cardiovascular health, and bone health. The partnership was initiated after Impli won a Bayer-sponsored innovation challenge at the HLTH Europe conference earlier this year. Both companies are committed to leveraging new technologies to create meaningful change and deliver better health outcomes for individuals.